八月 2026
- Home
- Inozyme
八月 2026的Inozyme市场份额分析
European laws, including the General Data Protection Regulation (“GDPR”) and the e-Privacy Directive 2002/58/EC, create obligations for digital publishers such as Inozyme Pharma (“Inozyme”) to give visitors of their sites and apps information about how they will use and share their personal data, as well as about the use of cookies, mobile ad IDs, and […]
Inozyme(包含公司地区分支机构)
查看更多网站流量和参与度信息- inozyme.com
Inozyme收入截至 八月 2026为 10M - 15M
Inozyme主要域名产生的收入
3 年中Inozyme主要域名的收入
Inozyme主要域名的收入
Inozyme热门域名的总访问量
了解Inozyme市场份额和潜在市场覆盖范围。
过去 3 个月的总访问量
子公司明细
Inozyme热门域名的平均访问时长
分析Inozyme参与度指标。
过去 3 个月的平均访问时长
子公司明细
Inozyme热门域名的平均页面浏览量
了解Inozyme如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。
过去 3 个月的平均页面浏览量
子公司明细
想要获取更深入的流量洞见?
过滤超过 2030 万家在线企业。发现流量激增的新潜在客户,开始或停止使用技术的新潜在客户,或者获得正面报道的新潜在客户。
Inozyme 的新闻与信号
借助 Similarweb 销售信号提醒,每当在目标受众之中出现新的机会或威胁时,您都会收到所识别出购买信号的每日更新。
新闻Duda leaves Inozyme Pharma, Inc. as Chief Medical Officer.Prior to joining GlycoEra, Dr. Duda served as Chief Medical Officer at Inozyme Pharma in Boston, MA, where she oversaw a clinical portfolio focused on rare and ultra-rare diseases and helped guide programs through key stages of development.
一月 1, 2026阅读更多
新闻Inozyme Pharma, Inc. launches JBMR Plus publication demonstrating real-world impact of ENPP1 Deficiency.Inozyme Pharma announces JBMR Plus publication demonstrating real-world impact of ENPP1 Deficiency.
四月 10, 2025阅读更多
新闻Inozyme Pharma, Inc. attends event 24th Annual Needham Virtual Healthcare Conference.Inozyme Pharma to participate in the 24th Annual Needham Virtual Healthcare Conference.
三月 31, 2025阅读更多
查看 Inozyme 的所有信号
让您的销售团队专注于最有希望的机会。通过分清机会的轻重缓急并在合适的时机介入,您可以优化工作并达成更多交易。
